vca-894a
Nucleic acidexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2025 (NCT07223632)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- DNA-binding protein SMUBP-2ANTISENSE INHIBITOR
IGHMBP2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223632 | Phase 1/Phase 2 (Phase 2) | May 13, 2025 | Vanda Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1